Abbisko will lead the study, with both companies jointly sharing clinical trial responsibilities.
Abbisko Therapeutics Co. Ltd. on Wednesday entered into a strategic collaboration with AstraZeneca Plc to jointly develop a ...
LONDON, June 4 (Reuters) - AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have ...
Tagrisso significantly improves overall survival in unresectable stage 3 EGFR-mutant NSCLC, surpassing placebo in the LAURA study. The FDA approved Tagrisso in September 2024 for patients with locally ...
AstraZeneca’s Tagrisso is already swimming in billions in annual sales after setting a new standard for treating metastatic EGFR-mutant non-small cell lung cancer. And now, with an FDA go-ahead in ...
After a massive tumor progression showing, AstraZeneca hopes new life extension data could expel whatever doubt that remains for using Tagrisso early in non-small cell lung cancer (NSCLC). Using ...
Tagrisso following chemoradiotherapy improved progression-free survival compared with placebo in stage 3 EGFR-mutated non–small cell lung cancer. Patients with locally advanced, unresectable (not able ...
Around 30,000 people annually in the U.S. with non-small cell lung cancer (NSCLC) also get diagnosed with specific epidermal growth factor receptor (EGFR) gene mutations, a condition that affects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results